Recombinant human TPO
-
Cat.code:
rcyc-htpoNEW
- Documents
ABOUT
Human TPO protein - Mammalian cell-expressed, tag-free, carrier-free
Recombinant human TPO is a high-quality and biologically active cytokine, validated using proprietary TPO reporter cells. This hematopoietic growth factor is produced in CHO cells to ensure protein glycosylation and bona fide 3D structure.
Recombinant human TPO can be used together with HEK-Blue™ TPO cells for screening molecules that activate or inhibit the TPO pathway, such as receptor agonists or monoclonal antibodies, respectively (see figures).
Key features
- Each lot is validated using HEK-Blue™ TPO cells
- Endotoxin ≤ 0.1 EU/µg
- 0.22 µm sterile-filtered
Applications
- Standard for TPO detection and quantification assays
- Screening and release assays for antibodies blocking TPO signaling
- Screening and release assays for engineered TPO
TPO is a key hematopoietic growth factor that plays a vital role in the regulation of megakaryocytopoiesis and the maintenance of hematopoietic stem cells (HSCs).
All InvivoGen products are for internal research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
P40225
100 μg/ml in water
Phosphate buffer saline (pH 7.0), 2.5% saccharose
0.22 µm filtration
The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK‑Blue™ TLR4 cells.
Cellular assays (tested), ELISA
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Recombinant human TPO
-
Cat code:rcyc-htpo
-
Quantity:10 µg
1.5 ml endotoxin-free water
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
TPO background
The hematopoietic growth factor thrombopoietin (TPO) plays a vital role in the regulation of megakaryocytopoiesis and the maintenance of hematopoietic stem cells (HSCs) [1]. TPO promotes the proliferation and differentiation of megakaryocytes and their specialized progenitors. Additionally, TPO drives platelet production and activity. The number of circulating platelets must be tightly controlled to avoid spontaneous bleeding or arterial occlusion and organ damage. TPO binding to the thrombopoietin receptor (TPO-R; also known as c-MPL) activates Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5), initiating the expression of TPO-inducible genes [2].
Relevance for therapeutics development
Abnormal levels of TPO or mutations in its receptor are associated with blood disorders, such as thrombocytosis and thrombocytopenia. Of note, TPO-R agonists have been successfully used to treat thrombocytopenia [3].
References:
1. Grozovsky R. et al., 2015. Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr Opin Hematol 22(5):445-51.
2. Hitchcock I., & Kaushansky K., 2014. Thrombopoietin from beginning to end. Br J Haematol. 165(2):259-68.
3. Ghanima W. et al., 2019. Thrombopoietin receptor agonists: ten years later. Haematologica. 104(6):1112-23.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?